Triazole beta carboline derivatives as antidiabetic compounds

Details Triazole beta carboline derivatives as antidiabetic compounds Triazole beta carboline derivatives as antidiabetic compounds

C - Chemistry, Metallurgy

07

D

C07D 471/04 (2006.01) A61K 31/437 (2006.01) A61K 31/444 (2006.01) A61P 3/00 (2006.01)

Patent

CA 2741259

Beta-carboline derivatives of structural formula (I) are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. Image

L'invention porte sur des dérivés de la bêta carboline présentant la formule structurelle (I), lesquels dérivés sont des antagonistes sélectifs du récepteur 3 du sous-type somatostatine (SSTR3), et qui sont utiles pour le traitement du diabète sucré de type 2 et de troubles qui sont souvent associés à cette maladie, y compris l'hyperglycémie, la résistance à l'insuline, l'obésité, les troubles lipidiques et l'hypertension. Les composés sont également utiles pour le traitement de la dépression et de l'anxiété.

Affiliated with

Also associated with

Rating

Triazole beta carboline derivatives as antidiabetic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Triazole beta carboline derivatives as antidiabetic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazole beta carboline derivatives as antidiabetic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2079986